1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. CONCORD BIOTECH LTD.
Concord Biotech Ltd.
NSE: CONCORDBIO | BSE: 543960

Concord Biotech Live Share Price Today, Share Analysis and Chart

Expensive Performer
aboutConcord Biotech Limited is a research and development-driven biopharmaceutical company specializing in the manufacture of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. Established with a focus on niche and com... Read More
Clinical TrialsPatent Approvals
Ask AI about Concord Biotech
1172.50-73.10(-5.87%)

27.40% Fall from 52W High

336.9K
NSE+BSE Volume

High volume+loss today

NSE 02 Nov, 2026 2:03 PM (IST)

Portfolio

Alert

My Notes

Bonus
Concord Biotech Ltd. has bonus in the ratio 1:1 with ex-date of 04 Nov 2026. See details
Loading...
- / 100
- / 100
44.8 / 100
Expensive PerformerThese stocks are strong in quality but with mid-range technicals. Their valuations are expensiveView SimilarEmbed DVM
Analyst Price Target
-

12

S

8

W

3

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

13Positive10Negative

Pass in checklist56.5%

045
55
100

Check P/E Buy Sell Zone

Buy Zone

26.0 %    into P/E buy sell zone

% time spent below current P/E
020406080100
Strong upside potential
Gains already realized

Concord Biotech Stock Price Analysis

Day Price Range

-5.9% 1 Day return
1172.5 (LTP)
1,1561,210
LowHigh

Week Price Range

-4.6% 1 Week return
1172.5 (LTP)
1,1561,393.9
LowHigh

Month Price Range

-14.7% 1 Month return
1172.5 (LTP)
1,1561,398.7
LowHigh

52 Week Price Range

-18.8% 1 Year return
1172.5 (LTP)
9871,615
LowHigh
View full Price History/Seasonality

Concord Biotech Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Concord Biotech's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
24.8
AVG. ESTIMATE
31.9
LOW ESTIMATE
31.1
HIGH ESTIMATE
32.7
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 28.8% in FY27

Consensus Recommendation

5 ANALYST Recommendations
BUY

The consensus recommendation from 5 analysts for Concord Biotech is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Concord Biotech Technical Analysis

Concord Biotech EMA & SMA

Bearish-8
0 bullish, 8 bearish
Bullish0
Bearish8
5 Day1266.7
10 Day1287.2
12 Day1294.8
20 Day1322.4
26 Day1338.7
50 Day1367.8
100 Day1357.6
200 Day1356.7

Concord Biotech Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202639.7%
Week38.9%
Month44.6%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Concord Biotech Resistance and Support

1244.37
Pivot
First Resistance1273.6
Second Resistance1301.7
Third Resistance1330.9
First Support1216.3
Second Support1187.1
Third Support1159.0
Day RSI39.7
Day MACD-43.9
Day MFI34.8
Day MACD Signal Line-39.4

Concord Biotech Beta

1 Month1.0
1 Year1
3 Month1.1
3 Year0.8

Concord Biotech Price Change Analysis

↓-14.7%
Over 1 Month
LowHigh
11561398.7
↓-17.5%
Over 3 Months
LowHigh
11561615
↑2.7%
Over 6 Months
LowHigh
1022.21615
↓-18.8%
Over 1 Year
LowHigh
9871615
All Technicals →

Concord Biotech Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Sudhir Kumar VaidPromoter30,169,52428.8 %
Government Pension Fund GlobalFii3,081,3623.0 %
TrustsPublic25,203,21724.1 %
Dsp Small Cap FundDii3,356,0653.2 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Concord Biotech Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
1575773 ONTARIO INCBulkSell31 Aug 20261404.102,092,325BSE
DSP MUTUAL FUNDBulkPurchase31 Aug 20261404.101,288,114BSE
NK SECURITIES RESEARCH PRIVATE LIMITEDBulkSell25 Feb 20261218.58616,952NSE
NK SECURITIES RESEARCH PRIVATE LIMITEDBulkPurchase25 Feb 20261217.94616,952NSE
UBS PRINCIPAL CAPITAL ASIA LIMITEDBulkSell20 Sep 20242589.86740,159NSE
THE VANGUARD GROUP INC A/C VANGUARD EMERGING MARKETS STOCK INDEX FUND A SERIES OF VANGUARD INTERNATBulkPurchase20 Sep 20242596.08577,183NSE
THE VANGUARD GROUP INC A/C VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUNDBulkPurchase20 Sep 20242596.08697,936NSE
1575773 ONTARIO INCBulkSell28 May 20241361.263,548,211NSE
NORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBALBulkPurchase28 May 20241386.95600,000NSE
BNP PARIBAS ARBITRAGEBlockSell25 Jan 20241421.70153,421BSE
All deals
All insider trades

Concord Biotech Corporate Actions

Concord Biotech Dividend history and yield

Concord Biotech dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Concord Biotech dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
124 Jul 2026
7.55FINAL24 Jul 2026Equity Share
203 Sep 2025
10.7FINAL03 Sep 2025Equity Share
321 Jun 2024
8.75FINAL22 Jun 2024Equity Share

Concord Biotech Bonus shares

Concord Biotech bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
104 Nov 2026
1:104 Nov 2026

Concord Biotech Board Meetings

Concord Biotech past and upcoming board meetings.

#Ex-Date
PurposeNotes
127 Oct 2026
Quarterly Results-
223 Sep 2026
Bonus issue-
331 Jul 2026
Quarterly Results-
429 May 2026
Audited Results & Final Dividend-
511 Feb 2026
Quarterly Results-
All Corporate Actions

Concord Biotech Research Reports

Concord Biotech research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
103 Aug 2023Hem Securities--IPO Subscribe--%pdf
203 Aug 2023SBI Securities--IPO Note--%-
303 Aug 2023HDFC Securities--IPO Note--%pdf
402 Aug 2023Ashika Research--IPO Note--%pdf
All Reports of Concord

Concord Biotech Corporate Filings

Concord Biotech BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
28 Oct 2026
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Earning Call Recording- For the Second Quarter and half year ended on September 30, 2026
PDF
28 Oct 2026
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 to be held on 03rd and 4th November, 2026.
PDF
28 Oct 2026
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Press release - For the Second quarter and half year ended on September 30, 2026
PDF
28 Oct 2026
Q2FY27 Quarterly Result Announced for Concord Biotech Ltd.
Biotechnology company Concord Biotech announced Q2FY27 results Consolidated Financial Highlights: Revenue from Operations: For Q2FY27, revenue from operations stood at Rs 30,907.02 lakh, registering a QoQ increase of 20.03% compared to Rs 25, 748.90 lakh in Q1FY27, and a YoY increase of 25.10% compared to Rs 24,705.75 lakh in Q2FY26. For H1FY27, it stood at Rs 56,655.92 lakh, up 25.61% YoY compared to Rs 45,104.51 lakh in H1FY26. Total Income: For Q2FY27, total income was Rs 31,923.95 lakh, which is an 18.10% increase QoQ against Rs 27,031.49 lakh in Q1FY27, and a 22.59% increase YoY against Rs 26,040.96 lakh in Q2FY26. For H1FY27, total income reached Rs 58,955.44 lakh, achieving a 23.32% YoY growth from Rs 47,807.48 lakh in H1FY26. Profit Before Tax (PBT): For Q2FY27, PBT stood at Rs 9,548.04 lakh, representing a QoQ growth of 21.87% compared to Rs 7,834.31 lakh in Q1FY27, and a YoY increase of 11.43% compared to Rs 8,568.40 lakh in Q2FY26. For H1FY27, PBT was Rs 17,382.33 lakh, growing by 20.36% YoY from Rs 14,441.59 lakh in H1FY26. Profit After Tax (PAT): For Q2FY27, PAT reached Rs 6,957.20 lakh, rising 20.58% QoQ from Rs 5,769.69 lakh in Q1FY27, and growing 10.32% YoY from Rs 6,306.28 lakh in Q2FY26. For H1FY27, PAT was Rs 12,726.87 lakh, a YoY expansion of 18.81% relative to Rs 10,712.07 lakh in H1FY26. Earnings Per Share (EPS): For Q2FY27, basic and diluted EPS was Rs 6.65, up 20.47% QoQ from Rs 5.52 in Q1FY27, and up 10.28% YoY from Rs 6.03 in Q2FY26. For H1FY27, EPS reached Rs 12.17, growing 18.85% YoY compared to Rs 10.24 in H1FY26. Standalone Financial Highlights: Revenue from Operations: For Q2FY27, standalone revenue from operations stood at Rs 31,231.38 lakh, increasing 19.88% QoQ relative to Rs 26,051.71 lakh in Q1FY27, and growing 26.41% YoY relative to Rs 24,705.75 lakh in Q2FY26. For H1FY27, it stood at Rs 57,283.09 lakh, gaining 27.00% YoY from Rs 45,104.51 lakh in H1FY26. Total Income: For Q2FY27, standalone total income was Rs 32,276.81 lakh, higher by 17.96% QoQ against Rs 27,361.35 lakh in Q1FY27, and higher by 23.91% YoY against Rs 26,048.66 lakh in Q2FY26. For H1FY27, it reached Rs 59,638.16 lakh, a 24.73% YoY growth compared to Rs 47,815.18 lakh in H1FY26. Profit Before Tax (PBT): For Q2FY27, standalone PBT stood at Rs 10,192.21 lakh, advancing 23.98% QoQ from Rs 8,220.96 lakh in Q1FY27, and expanding 19.18% YoY from Rs 8,551.75 lakh in Q2FY26. For H1FY27, standalone PBT was Rs 18,413.16 lakh, increasing by 28.98% YoY over Rs 14,275.71 lakh in H1FY26. Profit After Tax (PAT): For Q2FY27, standalone PAT reached Rs 7,571.39 lakh, climbing 23.73% QoQ from Rs 6,119.37 lakh in Q1FY27, and accelerating 20.38% YoY from Rs 6,289.63 lakh in Q2FY26. For H1FY27, standalone PAT was Rs 13,690.75 lakh, a 29.82% YoY increase compared to Rs 10,546.19 lakh in H1FY26. Earnings Per Share (EPS): For Q2FY27, standalone basic and diluted EPS was Rs 7.24, showing a QoQ growth of 23.76% from Rs 5.85 in Q1FY27, and a YoY increase of 20.47% from Rs 6.01 in Q2FY26. For H1FY27, standalone EPS stood at Rs 13.09, a 29.86% YoY growth against Rs 10.08 in H1FY26. Result PDF
PDF
27 Oct 2026
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor''s presentation on unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2026
PDF
VIEW ALL

Concord Biotech DocumentsAsk MarketMind AI

Concord Biotech Earnings Call

Concord Biotech earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
28 Oct 2026Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
07 Aug 2026Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
03 Aug 2026Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
03 Aug 2026Concord Biotech Results Earnings Call for Q1FY27AudioVideo
05 Jun 2026Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
view all

Concord Biotech Annual Reports

Concord Biotech financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link

Concord Biotech Credit Ratings

Concord Biotech credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
22 Sep 2026icra ratingsConcord Biotech LimitedRatings reaffirmedLink
22 Jul 2025icra ratingsConcord Biotech LimitedRatings reaffirmedLink
08 May 2024icra ratingsConcord Biotech LimitedRatings reaffirmedLink

Concord Biotech Investor Presentations

Concord Biotech investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
27 Oct 2026Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
01 Aug 2026Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
30 May 2026Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
11 Feb 2026Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
13 Nov 2025Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Concord Biotech - Company Profile

Concord Biotech Management Structure

Concord Biotech management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Devang BhattVice President(Sales & Marketing)-Mar 26
Mr. Manoj KumarVice President(Formulations)-Mar 26
Mr. Sundeep BenganiGeneral Manager(International Business Devpt)-Mar 26
ANKUR VAIDExecutive Director,Joint Managing Director,Chief Executive Officer-Mar 26
Mr. Raviraj KariaChief Financial Officer-Mar 26
Paritosh TrivediCompany Secretary,Compliance Officer-Mar 26

Concord Biotech Board of Directors

Concord Biotech Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
SUDHIR JAIRAM VAIDChairman / Executive Director / M D / Promoter706.73Mar 26
ANKUR VAIDED / Joint MD / CEO / Promoter390.86Mar 26
Amitabh ThakoreIndependent Non Exe. Director4.3Mar 26
Jayaram EaswaranIndependent Non Exe. Director4Mar 26
Arvind AgarwalIndependent Non Exe. Director3.7Mar 26
Mandayam Chakravarthy SriramanIndependent Non Exe. Director3.55Mar 26
Ravi KapoorNon-Exec & Non-Independent Dir3.4Mar 26
BHARTI KHANNAIndependent Non Exe. Director3.25Mar 26
Rajiv AgarwalNon-Exec & Non-Independent Dir2.95Mar 26
Paritosh TrivediCompany Sec. & Compli. Officer-Mar 26
EKTA GUPTAIndependent Non Exe. Director-Mar 26
Website: www.concordbiotech.com

About the company - Business Profile

Concord Biotech Limited is a research and development-driven biopharmaceutical company specializing in the manufacture of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. Established with a focus on niche and complex molecules, the company holds a significant position in the global immunosuppressant market. It operates across several therapeutic areas, including oncology, anti-fungal, and anti-infective treatments, utilizing its core expertise in fermentation and semi-synthetic processes.

Key Points

  • Key Facts:
    • Founded Year: 1984 (Operations commenced in 2000).
    • Headquarters: Ahmedabad, Gujarat, India.
    • Stock Listing: Listed on BSE (Scrip Code: 543960) and NSE (Symbol: CONCORDBIO).
    • Core Products: Fermentation-based APIs (Tacrolimus, Mycophenolate Mofetil, Cyclosporine) and finished formulations.
  • Operations and Resources:
    • Manufacturing Facilities:
      • Unit I (Dholka, Gujarat): API manufacturing facility focused on fermentation; operations began in FY2000.
      • Unit II (Valthera, Gujarat): Finished formulation facility; operations began in FY2016.
      • Unit III (Limbasi, Gujarat): Large-scale API manufacturing facility with an installed capacity of 800 cubic meters; operations began in FY2021.
      • Unit IV (Valthera, Gujarat): Newly commercialized injectable facility (FY2025) with an installed capacity of 13 million units.
    • R&D: Operates a DSIR-certified R&D facility with a team of over 180 specialists focused on strain improvement and process development.
  • Ownership and Market Significance:
    • The company transitioned from a private entity to a publicly listed company in August 2023.
    • It serves more than 70 countries globally, including regulated markets such as the US, Europe, and Japan.
    • Strategic importance lies in its role as one of the few global suppliers of complex fermentation-based APIs, which have high entry barriers due to technical complexity and stringent regulatory requirements.
  • Business Model and Expertise:
    • Concord Biotech operates an integrated business model encompassing R&D, API manufacturing, and formulation development.
    • It excels in Fermentation Technology, managing large-scale bio-processes for complex molecules.
    • The company also provides CDMO (Contract Development and Manufacturing Organization) services, leveraging its expertise in strain isolation and scalable fermentation processes.
  • Revenue Breakdown (FY 2024-25):
    • By Segment:
      • API: 78% (approx. ₹936 crore)
      • Formulations: 22% (approx. ₹264 crore)
    • By Geography:
      • Exports: 55% (approx. ₹660 crore)
      • Domestic: 45% (approx. ₹540 crore)
    • Total Revenue from Operations (Annual FY25): ₹1,200.09 crore.
  • Key Products and Technology:
    • Portfolio: Over 30 fermentation APIs and 100+ approved formulation products.
    • Key Molecules: Tacrolimus, Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, and Everolimus.
    • Regulatory Assets: 140+ Drug Master Files (DMFs) filed globally.
    • Recent Advancements: Commissioned a new injectable facility at Valthera and received WHO-GMP certification for it in 2025. Established a US subsidiary, Stellon Biotech, to manage direct marketing and distribution in the United States.
  • Partnerships and Human Capital:
    • Collaborates with leading global innovator pharmaceutical companies for API supplies.
    • Employee Count: Maintains a specialized workforce (specific headcount for FY25 not detailed, but includes 180+ in R&D).
  • Strategic Initiatives and Outlook:
    • Geographic Expansion: Focused on deeper penetration in the US through the Stellon Biotech subsidiary and expanding in the European Union following CDSCO certification renewals.
    • Product Diversification: Scaling up the injectable portfolio and increasing CDMO engagements.
    • Financial Health: The company remains debt-free with a net worth of ₹1,812.72 crore as of March 2025.

References

  1. Annual Report May 2025
  2. Investor Presentation Feb 2026
  3. Investor Presentation Nov 2025
  4. Annual Report May 2024

Concord Biotech FAQ

Concord Biotech today is trading in the red, down by 5.87% at ₹1,172.5.
Concord Biotech is currently trading down 5.87% on an intraday basis. In the past week the stock fell 4.62%. Stock has been down 17.48% in the past quarter and fell 18.79% in the past year. You can view this in the share price history/seasonality section.
Concord Biotech is listed on NSE with the ticker CONCORDBIO and on BSE as 543960. It's currently trading on NSE at a share price of ₹1,172.5 and on BSE with a share price of ₹1,170.
The market cap of Concord Biotech is ₹12,266.25 Cr. as of Nov 02, 2026.
Concord Biotech announced a FINAL dividend of 755% which equals ₹7.55 in Jul 24, 2026.The last two ex-dates for Concord Biotech were Sep 03, 2025 and Jun 21, 2024. To view the full dividend history of Concord Biotech click here.
Concord Biotech has never issued stock splits, but it has issued 1 bonus shares since its BSE/NSE listing. The latest announcement for Concord Biotech bonus shares was on Nov 04, 2026 at a ratio of 1:1.
Concord Biotech reported ₹319.24 Cr. in revenue, ₹70.65 Cr. in net profit, and ₹114.55 Cr. in EBITD as of Oct 27, 2026 for Q2 FY26-27.
According to the predictions of 5 analysts, the share price prediction for Concord Biotech is ₹1,520 with an upside of 30%.
The PE ratio of Concord Biotech is 43.43 as of Nov 02, 2026.
The PB ratio of Concord Biotech is 5.92 as of Nov 02, 2026.
There are no analyst reports for Concord Biotech.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×